Amlodipine And Olmesartan Medoxomil In Hypertensive Filipino Patients

• Status: Terminated
• Trial end date: 2014-01-04
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine the safety, tolerability and efficacy of Amlodipine and Olmesartan medoxomil among Hypertensive Filipino patients.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Amlodipine; Amlodipine Besylate, Olmesartan Medoxomil Drug Combination; Olmesartan; Olmesartan Medoxomil

Criteria

Inclusion Criteria:

• Filipino hypertensive subjects ages 18-65 years old whether naive or currently taking any other anti-hypertensive or those on monotherapy using CCBs or ARBs whom they want to shift on a fixed dose combination drug

Exclusion Criteria:

• Patients with contraindications to any of the component of the fixed drug (amlodipine or olmesartan medoxomil) or with malignant or secondary hypertension